AstraZeneca

In News

AstraZeneca eyes 5th Ultomiris indication after kidney disease trial win - Fierce Pharma

Fierce Pharma - Apr 21, 2026

Germany risks missing out on new drugs, AstraZeneca CEO tells paper - Reuters

Reuters - Apr 21, 2026

AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win - Fierce Biotech

Fierce Biotech - Apr 20, 2026

AstraZeneca slides Tuesday, underperforms market - MarketWatch

MarketWatch - Apr 21, 2026

AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data - Clinical Trials Arena

Clinical Trials Arena - Apr 22, 2026

Carvykti shows promise before multiple myeloma; two megarounds; AZ wins in COPD and kidney disease - Endpoints News

Endpoints News - Apr 21, 2026

AstraZeneca’s Baxdrostat Trial Completion Puts Resistant Hypertension Opportunity in Focus - TipRanks

TipRanks - Apr 21, 2026

AstraZeneca's Ultomiris cuts urine protein in late-stage kidney disease trial - Yahoo

Yahoo - Apr 21, 2026

AstraZeneca's tozorakimab delivers reduction in chronic lung disease flare‑ups - Reuters

Reuters - Apr 20, 2026

AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed - CNBC

CNBC - Mar 27, 2026

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD - AstraZeneca

AstraZeneca - Apr 20, 2026

AstraZeneca warns German reforms could push pharma launches and investment out of Europe - EU Reporter

EU Reporter - Apr 22, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment